Light Sciences Adipose to Present at Medtech Insight and Windhover Information's ``In3 Medical Device Summit'' Conference, June 21-23, 2006 in San Francisco, CA.

SAN FRANCISCO -- Light Sciences Adipose has announced that it will be presenting on June 22, 2006 at 11:20 a.m. at Medtech Insight and Windhover Information's "In3 Medical Device Summit" Conference, June 21-23, 2006 at The Palace Hotel in San Francisco, CA.

Light Sciences Adipose is further developing a combination drug/device therapeutic system to safely reduce visceral fat with minimally invasive methods. Research suggests that when visceral fat is removed or reduced, insulin resistance may be improved or reversed. During treatment with the Light Sciences Adipose system, the patient is given an intravenous injection of a photosensitizing drug followed by placement of a small probe (light catheter) that is about one millimeter in diameter. The light catheter is placed under CT or laparoscopic guidance into the tissues to be reduced. The inserted end of the catheters house light-emitting diodes that are activated for approximately one hour, after which the catheter is removed. The adipose cells should gradually break down and be reabsorbed, leading to a reduced volume of visceral fat with a subsequent decrease of insulin resistance.

Reversal of insulin resistance using the Light Sciences Adipose system may ultimately help prevent more serious and costly complications of diabetes, such as cardiovascular disease, renal failure, peripheral vascular disease, and diabetic retinopathy.

The initial potential patient population includes obese individuals with recently diagnosed type 2 diabetes, about 8.5 to 9 million people in the United States. In the future it may be possible to expand to individuals with pre-diabetes, an additional 12 million people in the United States.

Light Sciences Adipose is also developing a similar system for aesthetic use. It is envisioned that the system could be used to selectively reduce subcutaneous fat deposits in areas such as the outer thigh. The American Society of Plastic Surgeons has estimated that 324,000 liposuction procedures were performed in 2005. The Light Sciences Adipose system would offer a minimally invasive treatment to augment or replace liposuction.

About Light Sciences Adipose

Light Sciences Adipose is a wholly owned subsidiary of Light Sciences Corporation (LSC), a privately-owned company located in Snoqualmie, WA, outside of Seattle. LSC was founded in 1995 as a limited partnership and incorporated in August 2000. By 2004 development of Light Infusion Technology(TM) (Litx(TM)) had progressed to a stage that enabled LSC to create specialized subsidiaries to focus further development of Litx(TM) on three distinct business opportunities: Oncology, Ophthalmology and Cardiology. Light Sciences Oncology received venture funding in October 2005 and was spun-off as an independent company. Following this, LSC created Light Sciences Adipose to develop Litx(TM) in the area of bariatric medicine and endocrinology.

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. The In3 Medical Device Summit (www.meddevicesummit.com) is Medtech Insight's 21st investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.